Select publications

Berdeja JG et al. Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. Biol Blood Marrow Transplant 2001;7(10)561-7. Abstract

Czuczman MS et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23(4):694-704. Abstract

Flinn IW et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2000;6(6):628-32. Abstract

Flinn IW, Lazarus HM. Monoclonal antibodies and autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 2001;27(6):565-9. Abstract

Herold M et al. Results of a prospective randomized open label phase III study comparing rituximab plus mitoxantrone, chlorambucil, prednisone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin’s lymphoma (NHL) and mantle-cell lymphoma (MCL). Blood 2004;104(11);Abstract 584.

Hochster HS et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Proc ASCO 2004;Abstract 6502.

Kasamon YL et al. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2005;11(1):39-46. Abstract

Malek SN, Flinn IW. Incorporating monoclonal antibodies in blood and marrow transplantation. Semin Oncol 2003;30(4):520-30. Abstract

Van Oers MHJ et al. Chimeric anti-CD20 monoclonal antibody (rituximab; MabThera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: A Phase III randomized Intergroup clinical trial. Proc ASH 2004;Abstract 586.

Williams ME. ECOG 4402: Randomized Phase III trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin’s lymphoma. Curr Hematol Rep 2004;3(6):395-6. No abstract available